The article discusses the immune responses to SARS-CoV-2 infection, highlighting the two-phase immune response: an initial adaptive immune response during the incubation and non-severe stages, and a subsequent inflammatory response in severe cases. The first phase involves the body's ability to eliminate the virus and prevent progression to severe illness. The second phase is characterized by a damaging inflammatory response, particularly in the lungs, leading to life-threatening respiratory disorders. The role of asymptomatic carriers in spreading the virus is also discussed, emphasizing the need for effective strategies to manage these individuals. The article also explores the impact of HLA haplotypes on susceptibility to SARS-CoV-2 infection and the development of immunity. Certain HLA alleles are associated with increased susceptibility or resistance to various infectious diseases, including SARS-CoV-2. Understanding these genetic factors could aid in the development of targeted therapies and vaccines. The role of hyaluronan (HA) in the progression of severe COVID-19 is discussed, with HA being implicated in the development of acute respiratory distress syndrome (ARDS). HA's ability to absorb water makes it a potential target for treatment, with hyaluronidase and inhibitors of HA synthesis being proposed as therapeutic options. The article also suggests the use of mesenchymal stem cells and vitamin B3 in the treatment of severe cases. These approaches aim to reduce inflammation, promote tissue repair, and improve lung function. The importance of early intervention, including the use of hyaluronidase and 4-MU, is emphasized to prevent the progression of the disease. Overall, the article underscores the importance of understanding the immune response to SARS-CoV-2 and developing targeted interventions to manage the disease effectively. The two-phase immune response model provides a framework for understanding the progression of the disease and guiding treatment strategies.The article discusses the immune responses to SARS-CoV-2 infection, highlighting the two-phase immune response: an initial adaptive immune response during the incubation and non-severe stages, and a subsequent inflammatory response in severe cases. The first phase involves the body's ability to eliminate the virus and prevent progression to severe illness. The second phase is characterized by a damaging inflammatory response, particularly in the lungs, leading to life-threatening respiratory disorders. The role of asymptomatic carriers in spreading the virus is also discussed, emphasizing the need for effective strategies to manage these individuals. The article also explores the impact of HLA haplotypes on susceptibility to SARS-CoV-2 infection and the development of immunity. Certain HLA alleles are associated with increased susceptibility or resistance to various infectious diseases, including SARS-CoV-2. Understanding these genetic factors could aid in the development of targeted therapies and vaccines. The role of hyaluronan (HA) in the progression of severe COVID-19 is discussed, with HA being implicated in the development of acute respiratory distress syndrome (ARDS). HA's ability to absorb water makes it a potential target for treatment, with hyaluronidase and inhibitors of HA synthesis being proposed as therapeutic options. The article also suggests the use of mesenchymal stem cells and vitamin B3 in the treatment of severe cases. These approaches aim to reduce inflammation, promote tissue repair, and improve lung function. The importance of early intervention, including the use of hyaluronidase and 4-MU, is emphasized to prevent the progression of the disease. Overall, the article underscores the importance of understanding the immune response to SARS-CoV-2 and developing targeted interventions to manage the disease effectively. The two-phase immune response model provides a framework for understanding the progression of the disease and guiding treatment strategies.